

Bulletin from Egetis Therapeutics' Annual General Meeting 2021

Stockholm, Sweden, April 29, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that the Annual General Meeting (AGM) has been held on April 29, 2021, at which meeting submitted proposals were passed. The complete resolution proposals are stated in the AGM notice.

In light of the ongoing pandemic and in order to minimize any risk of spreading of the corona virus, the meeting was held through postal voting in accordance with temporary legislation. Among other items of business, the following resolutions were taken:

The income statements and balance sheets were adopted, together with the Board of Directors' proposal for disposition of the company's result. The Board of Directors and CEO were discharged from liability for the financial year 2020.

Dr Gunilla Osswald, Dr Elisabeth Svanberg and Dr Peder Walberg were re-elected and Dr Thomas Lönnngren and Mats Blom were elected as Directors of the Board. Dr Thomas Lönnngren was elected as Chairman of the Board.

The AGM voted on directors' fees in accordance with the Nomination Committee's proposal, i.e. that fees to the Board members and to the Chairman of the Board should be paid as follows:

Total remuneration to the Board will amount to SEK 1,260,000. The Chairman of the Board will receive SEK 600,000 and each of the other Board members will receive SEK 165,000. Remuneration to the auditor shall be paid according to approved invoices.

BDO Mälardalen AB was re-elected auditor for the period until the close of the AGM 2022. It was noted that Authorized Public Accountant Karin Siwertz will replace Jörgen Lövgren as the Auditor in Charge.

The Nomination Committee's proposal regarding the establishment of a Nomination Committee and Nomination Committee instructions was approved.

The remuneration guidelines for senior management was approved by the AGM.

The AGM approved the Board of Directors' remuneration report for 2020.

The AGM approved the proposal from the Board of Directors regarding the introduction of an employee stock option program and a directed issue of warrants as well as approved the transfer of warrants.

The AGM voted in favor of the Board of Directors' proposal regarding an authorization to issue shares, warrants and/or convertibles. The Board shall, however, not be able to make decisions which mean that the share capital is increased by more than ten (10) percent in relation to the share capital that applied the first time the authorization was exercised.

Minutes with complete resolutions from the AGM will be made available on the company's website, www.egetis.com



PRESS RELEASE

29 April 2021 15:30:00 CEST

For further information, please contact

Nicklas Westerholm, CEO,
Phone: +46 73 354 20 62
E-mail: nicklas.westerholm@egetis.com

Marie-Louise Alamaa, Interim CFO
Tel +46 (0) 70 861 88 42
E-mail: marie-louise.alamaa@egetis.com

About Egetis Therapeutics

Egetis Therapeutics is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial has been completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study has been initiated with the first patient dosed in Dec 2020 and interim results are expected in 2022. Emcitate holds Orphan Drug Designation (ODD) in the US and EU and was granted Rare Pediatric Disease Designation by the US FDA in November 2020. The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted Orphan Drug Designation in the US and an application for ODD was submitted in Europe in Q1 2021. Results from the PledOx POLAR program in Dec 2020 showed that PledOx did not meet the efficacy endpoint. After discussion with our partner Solasia, Egetis Therapeutics has decided to park the development of PledOx following the POLAR results.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market. For more information, see <http://www.egetis.com/>

Attachments

[Bulletin Annual General Meeting 2021](#)
[Bulletin from Egetis Therapeutics' Annual General Meeting 2021](#)